Effects of a new selective β3‐adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease
- 18 September 2023
- journal article
- research article
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 15 (6) , 265-270
Abstract
Objectives: Parkinson's disease caused by the loss of dopaminergic neurons induces not only motor dysfunction but also lower urinary tract dysfunction. Patients with Parkinson's disease have recently been reported to experience both urge urinary incontinence (overactive bladder) and stress urinary incontinence, the latter of which occurs when the pressure of the bladder exceeds that of the urethra. Vibegron is a highly selective novel β3‐adrenoceptor agonist approved for the treatment of overactive bladder. However, how β3‐adrenoceptor agonists affect urethral function remains unclear. In a clinical report, the urethral function of patients with Parkinson's disease was shown to be degraded. The present study aimed to investigate the effects of vibegron on lower urinary tract activity in a rat model of Parkinson's disease.Methods: In a rat model of Parkinson's disease induced by unilateral 6‐hydroxydopamine injection into the substantia nigra pars compacta, we examined the effects of vibegron on bladder and urethral activity.Results: Cystometric analysis revealed that, compared with vehicle injection, intravenous injection of 3 mg/kg vibegron significantly increased the inter‐contraction interval (p < .05) and reduced voiding pressure (p < .01). However, no significant effects on urethral function were observed.Conclusions: The results of the present study provide corroborating evidence that bladder dysfunction is suppressed by the administration of vibegron in Parkinson's disease model rats, confirming that vibegron is effective for treating overactive bladder without further worsening urethral function. These findings may contribute to a better understanding of the mechanisms of β3‐adrenoceptor agonists.Keywords
Funding Information
- Japan Society for the Promotion of Science (22K09490)
This publication has 32 references indexed in Scilit:
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the diseaseBritish Journal of Pharmacology, 2011
- Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literatureInternational Journal Of Clinical Practice, 2011
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Changes in Prevalence and Incidence of Parkinson’s Disease in Japan during a Quarter of a CenturyNeuroepidemiology, 2009
- Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6‐hydroxydopamine (6‐OHDA) lesion of the nigrostriatal pathwayBritish Journal of Pharmacology, 2003
- Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophyJournal of Neurology, Neurosurgery & Psychiatry, 2001
- URETHRAL AFFERENT NERVE ACTIVITY AFFECTS THE MICTURITION REFLEX; IMPLICATION FOR THE RELATIONSHIP BETWEEN STRESS INCONTINENCE AND DETRUSOR INSTABILITYJournal of Urology, 1999
- Functional and molecular biological evidence for a possible β3‐adrenoceptor in the human detrusor muscleBritish Journal of Pharmacology, 1999
- The Influence ofβ-Adrenoceptor and Muscarinic Receptor Agonists and Antagonists on the Static Urethral Closure Function in Healthy FemalesScandinavian Journal of Urology and Nephrology, 1993
- 6-hydroxy-dopamine induced degeneration of central monoamine neuronsEuropean Journal of Pharmacology, 1968